[Prospects of using immunocorrective treatment with an active thymus factor (taktivin) in dermatology].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000187:drug effects; D002908:Chronic Disease; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D011711:Pyoderma / Q000188:drug therapy / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects; D013949:Thymus Extracts / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; D013951:Thymus Hormones; C036191:T-activin
Perspektivy primeneniia immunokorrigiruiushchego lecheniia aktivnym faktorom timusa (taktivinom) v dermatologii.